After J&J sale, Cambridge investor sets sights on $175M raise for new medtech VC firm

After J&J sale, Cambridge investor sets sights on $175M raise for new medtech VC firm

Source: 
Bizjournals
snippet: 

What will the next life sciences unicorn be? If you ask venture capitalist Chris Velis’ son, it could come from his new Cambridge investment firm.

“Dad, I get it. You don’t search for unicorns. You breed them,” Velis recalled one of his sons saying during a recent meeting at the Harvard Square headquarters of his new medtech-focused venture creation firm, Miraki Innovation.